From the browser to the back end, the ‘boring’ choice is exciting again. We look at three trends converging to bring SQL back ...
Cerevance has said it plans to move on to late-stage trials of its first-in-class Parkinson's disease drug CVN424 after hitting the mark in a phase 2 proof-of-concept study. The Boston-based biotech ...
How SMBs use threat research and MDR to build a defensive edge We speak to Director of ESET Threat Research Jean-Ian Boutin about where solutions that blend advanced technology with human expertise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results